StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 4.4 %
Shares of NASDAQ:TTNP opened at $5.05 on Friday. Titan Pharmaceuticals has a 1 year low of $4.24 and a 1 year high of $14.80. The stock has a 50-day simple moving average of $5.94 and a 200-day simple moving average of $6.40.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Technology Stocks Explained: Here’s What to Know About Tech
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 5 discounted opportunities for dividend growth investors
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
